A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
Key facts
- Who runs it
- Cerium Pharmaceuticals, Inc.
- Where
- Atlanta, Boynton Beach, Brunswick, Charlottesville, Chicago, Coral Springs, Fairfax, Fort Lauderdale, Houston, Iowa City, Los Angeles, Lufkin, Miami, New York, Saint Clair Shores, San Dimas, Tampa, and Tarzana, United StatesSee the 19 sitesAlso in 2 other countries, 12 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 148 people, planned
- Started
- 13 Mar 2023
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- SNP-ACTH (1-39) Gel
- Rituximab
- Record updated
- 25 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Biopsy-proven membranous glomerulonephritis or a diagnosis of MN in patients with Nephrotic Syndrome and a positive anti PLA2R antibody test
- Patients classified to be at a High Risk for progressive loss of kidney function, as defined by Kidney Disease Improving Global Outcomes (KDIGO) 2021-Glomerular Diseases Guideline
- eGFR by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula ≥40 mL/min/1.73 m\^2
- Patients who have had CR or PR in response to immunosuppressive therapy, but then relapsed can participate in the study if it has been more than 3 months since their last dose of high dose glucocorticoids, calcineurin inhibitors or mycophenolate mofetil
- Patients who have had CR or PR in response to IS therapy, but then relapsed can participate in the study if it has been more than 6 months since their last dose of chlorambucil or cyclophosphamide
- Patients who have had CR or PR in response to immunosuppressive therapy, but then relapsed can participate in the study if it has been more than 12 months since their last dose of rituximab
- Life expectancy > 24 months
- Other inclusion criteria may apply
Who cannot take part
- Patients who must be initiated on drugs likely to affect renal function if not properly dosed
- Surgery within 1 month of study entry
- Type 1 or 2 diabetes mellitus
- History of sensitivity to proteins of porcine origin
- Patients who have had a ≥ 50% reduction in serum titers of PLA2R auto-antibody within 1 year before screening
- Secondary membranous nephropathy as defined by history, physical exam, kidney biopsy results or serologies
- Other exclusion criteria may apply
Where in United States
Also in 2 other countries, 12 sites
- Fides Clinical ResearchAtlanta, United StatesContact: Nancy Klett, MPHTaking people
- Reciomed Clinical Research Network, Inc.Boynton Beach, United StatesContact: Nancy Klett, MPHTaking people
- Costal Medical ResearchBrunswick, United StatesContact: Nancy Klett, MPHTaking people
- University of VirginiaCharlottesville, United StatesContact: Nancy Klett, MPHTaking people
- Insight Hospital and Medical Center ChicagoChicago, United StatesContact: Nancy Klett, MPHTaking people
- South Florida Nephrology ResearchCoral Springs, United StatesContact: Nancy Klett, MPHTaking people
- Nephrology Associates Of Northern VirginiaFairfax, United StatesContact: Nancy Klett, MPHTaking people
- Therafirst Medical CenterFort Lauderdale, United StatesContact: Nancy Klett, MPHTaking people
- Prolato Clinical Research CenterHouston, United StatesContact: Nancy Klett, MPHTaking people
- University of IowaIowa City, United StatesContact: Nancy Klett, MPHTaking people
- Academic Medical Research InstituteLos Angeles, United StatesContact: Nancy Klett, MPHTaking people
- P&I Clinical Research, LLCLufkin, United StatesContact: Nancy Klett, MPHTaking people
- Reliant Medical Research LLCMiami, United StatesContact: Nancy Klett, MPHTaking people
- Vista Health Research, LLCMiami, United StatesContact: Nancy Klett, MPHTaking people
- NYU Langone HealthNew York, United StatesContact: Nancy Klett, MPHTaking people
- Center for Advanced Kidney Research, PLCSaint Clair Shores, United StatesContact: Nancy Klett, MPHTaking people
- North America Research InstituteSan Dimas, United StatesContact: Nancy Klett, MPHTaking people
- Genesis Clinical ResearchTampa, United StatesContact: Nancy Klett, MPHTaking people
- Valiance Clinical ResearchTarzana, United StatesContact: Nancy Klett, MPHTaking people
About the trial
What the trial wants to find out
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membranous nephropathy (PMN) at month 24.
The 4 groups in the trial
- Phase 3a Cohort 1Treatment being tested
3 mg SNP-ACTH Gel sc injection 3 times per week
Treatment: SNP-ACTH (1-39) Gel
- Phase 3a Cohort 2Treatment being tested
5 mg SNP-ACTH Gel sc injection 3 times per week
Treatment: SNP-ACTH (1-39) Gel
- Phase 3b Cohort 1Treatment being tested
Dose level to be confirmed once Phase 3a part is completed
Treatment: SNP-ACTH (1-39) Gel
- Phase 3b Cohort 2Existing treatment, for comparison
Rituximab arm: Patients randomized to the rituximab arm will receive 1 g IV infusion on T0 (after baseline measures are collected) and day 15. A second course of rituximab 1g IV infusion will be administered 6 months after the first rituximab infusion and an additional 1 g IV infusion 14 days following the first 6-month infusion.
Treatment: Rituximab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3 Superiority Study Comparing the Safety and Efficacy of SNP-ACTH (1-39) Gel Compared to Rituximab and FDA Approved Biosimilars in Adults With Primary Membranous Nephropathy (PMN) in a Two-Phase Adaptive Trial Design
- Record updated
- 25 June 2026